[CAS NO. 344897-95-6] Leukadherin-1

Name: Leukadherin-1
Brand: Arctom Scientific
SKU: SLK-S8306

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [344897-95-6]

Store

Catalog

SLK-S8306

Brand

Selleck

CAS

344897-95-6

DESCRIPTION [344897-95-6]

Overview

MDL	MFCD01151276
Molecular Weight	421.49
Molecular Formula	C22H15NO4S2
SMILES	O=C(O)C1=CC=C(C2=CC=C(C=C(SC(N3CC4=CC=CC=C4)=S)C3=O)O2)C=C1

For research use only.

Storage

3 years,-20°C,powder
1 years,-80°C,in solvent

Shipping

Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Concentration Volume Mass	1 mg	5 mg	10 mg
1 mM	2.3725 mL	11.8627 mL	23.7254 mL
5 mM	0.4745 mL	2.3725 mL	4.7451 mL
10 mM	0.2373 mL	1.1863 mL	2.3725 mL
50 mM	-	-	-

Description

Leukadherin-1 (LA1) is a small molecule agonist that enhances CD11b/CD18-dependent cell adhesion to its ligand ICAM-1(an agonist for the complement receptor 3 ()).

Targets

CD11b/CD18 ^[3]

In vitro

Leukadherin-1 pretreatment reduces secretion of interferon (IFN)-γ, tumour necrosis factor (TNF) and macrophage inflammatory protein (MIP)-1β by monokine-stimulated NK cells. It also reduces secretion of IL-1β, IL-6 and TNF by Toll-like receptor (TLR)-2 and TLR-7/8-stimulated monocytes. Leukadherin-1 modulates NK cell cytokine secretion and does not modulate Syk activation in NK cells. LA1 increases CD11b/CD18-dependent cell adhesion to fibrinogen with 50% effective concentration (EC50, the effective concentration for a 50% increase in adhesion) values of 4 μM.

In vivo

Leukadherin-1 has potent anti-inflammatory effects in a range of animal models, including an autoimmune nephritis model, without obvious short-term side effects. Leukadherin-1 (LA1) increases leukocyte adhesion, preventing their transmigration and tissue recruitment in vivo. LA1 treatment reduces interstitial leukocyte infiltration in the allograft, reduces neointimal hyperplasia and glomerular damage, and prolongs graft survival from 48.5% (CsA only) to 100% (CsA and LA1) on day 60 in a mouse model of fully MHC-mismatched orthotopic kidney transplantation.

References

[1] Roberts AL, et al. Clin Exp Immunol. 2016, 185(3):361-71.
[2] Khan SQ, et al. Front Med (Lausanne). 2014, 1:45.
[3] Maiguel D, et al. Sci Signal. 2011, 4(189):ra57.